Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors

NCT07196579 is registered in ClinicalTrials.gov with TCRx Therapeutics Co.Ltd as lead sponsor.

NCT NCT07196579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07196579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors
Lead sponsor
TCRx Therapeutics Co.Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 1, 2025
Completion date
December 31, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid cancer